Leaders of the Senate Homeland Security and Governmental Affairs Committee late Wednesday announced a new bipartisan investigation into risky life science research, amid ongoing tensions with Chinese biopharma service providers with a new bill targeting the companies making headway in both the House and Senate.
Sens. Gary Peters (D-MI) and Rand Paul (R-KY) said they plan to hold hearings and dig into everything from “high-risk life science research, biodefense, synthetic biology, biosafety and biosecurity lapses,” to “early warning capabilities for emerging outbreaks or possible attacks, and potential origins of the COVID-19 pandemic.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.